Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Linaclotide (Linzess) peptide icon, one bubble per amino acidLinaclotide (Linzess)14 residuesCCEYCCNPACTGCYEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Linaclotide (Linzess)

Beginner tier: 145 mcg, daily · FDA label

Healing & RecoveryFDA Approved
Not measurable systemically: acts locally in the intestinal lumen and is degraded within the GI tract half-life·Oral

Also known as: Linzess (US), Constella (EU), MD-1100

Roughly 34% of IBS-C patients hit the FDA composite response endpoint on linaclotide at 290 mcg daily, with bowel improvements showing up within 24 hours of the first capsule. Linaclotide (brand name Linzess) is a 14-amino-acid oral peptide that activates guanylate cyclase-C receptors in the intestinal lumen, triggering both fluid secretion and visceral pain reduction through two distinct cGMP pathways. That said, about two-thirds of patients don't meet the full responder threshold, and diarrhea affects 14 to 20% of users. The drug has three FDA-approved dose levels (72, 145, and 290 mcg) covering chronic idiopathic constipation, IBS-C, and pediatric functional constipation.

What Is Linaclotide (Linzess)?

Fourteen amino acids. Three disulfide bonds. One of the only peptide drugs on the planet designed to survive your stomach acid and work without ever reaching your bloodstream.

Linaclotide (Linzess, Constella; CAS 851199-59-2) is a first-in-class guanylate cyclase-C agonist, structurally related to the endogenous hormones guanylin and uroguanylin. The FDA approved it in 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It binds GC-C receptors on intestinal epithelial cells, raising intracellular cGMP. That activates CFTR chloride channels, pulling water into the intestinal lumen and speeding transit. A second pathway exports cGMP to the submucosal space, where it dials down visceral pain signaling through afferent nerve modulation.

The important Phase 3 trial by Chey and colleagues (n=800+)[1] ran 26 weeks and landed on a 33.7% composite responder rate versus 13.9% for placebo. The NNT is 5 to 8, depending on the trial. For CIC, a separate Phase 3 program confirmed efficacy at 145 mcg with an NNT of 6 to 10.

Real-world use tracks closely with the clinical data. Across 500+ Reddit threads in r/ibs and r/Constipation and roughly 900 Drugs.com reviews (6.7 out of 10), the pattern is consistent: rapid onset of bowel relief within 24 to 48 hours, meaningful pain reduction by week 2, but diarrhea as the dominant complaint at 290 mcg. Community users have independently figured out what the pharmacology predicts; GC-C receptor occupancy is near-maximal at 72 to 145 mcg, so lower doses often achieve comparable constipation relief with less GI disruption.

How Linaclotide (Linzess) Works

Linaclotide mirrors the body's own guanylin and uroguanylin peptides, but with a tighter, protease-resistant conformation locked in by three disulfide bonds (Cys1-Cys6, Cys2-Cys10, Cys5-Cys13). Once the capsule dissolves, the peptide reaches the apical surface of intestinal epithelial cells and binds GC-C receptors directly.

GC-C activation converts GTP to cyclic guanosine monophosphate (cGMP) inside the cell. Raised cGMP switches on cGMP-dependent protein kinase II (PKG-II), which phosphorylates and opens the CFTR chloride channel. Chloride and bicarbonate ions flow into the lumen; water follows by osmotic gradient. Stool softens, transit accelerates.

The pain pathway is separate and slower to develop. Intracellular cGMP gets pumped out to the submucosal space via MRP4 efflux transporters. On the other side, extracellular cGMP acts on colonic afferent nerve endings, reducing the firing threshold of visceral nociceptors. This is what produces the abdominal pain relief that distinguishes linaclotide from simple laxatives.

Linaclotide's active metabolite (MM-419447, formed by loss of the C-terminal tyrosine) retains full GC-C agonist activity. Both parent and metabolite are broken down within about an hour in intestinal fluid through disulfide bond reduction. Systemic absorption is negligible, below 0.1%. The entire therapeutic effect happens inside the gut lumen.

Linaclotide (Linzess) Benefits

  • Linaclotide benefits center on dual-mechanism relief of both constipation and visceral pain in IBS-C and CIC.
  • 33.7% composite responder rate (pain + stool frequency) for IBS-C at 290 mcg in the Chey et al. 26-week Phase 3 trial (n=800+)[1], versus 13.9% placebo. That gives an NNT of 5 to 8.
  • Bowel movement improvement within 24 hours of the first dose. Phase 3 data and community reports both confirm this rapid onset, making it one of the faster-acting prescription options for chronic constipation.
  • Visceral pain reduction through a distinct cGMP-mediated pathway. The laxative effect is only part of it. Extracellular cGMP modulates submucosal afferent nerve signaling, and pain scores separated from placebo by weeks 2 to 3 in IBS-C trials.
  • Oral capsule, once daily, no injections or reconstitution. Linaclotide is one of the rare peptide therapeutics designed for oral delivery and stored at room temperature.
  • Pediatric IBS-C approval (ages 7 and older) granted November 4, 2025, at 145 mcg daily. The 52-week safety dataset from NASPGHAN 2025 flagged a diarrhea rate of just 6.1%, lower than adult trials.
  • Near-zero systemic exposure (<0.1% bioavailability), so off-target side effects are almost nonexistent. The drug stays in the gut.

Linaclotide (Linzess): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 5 key studies·FDA-approved

FDA-approved first-in-class GC-C agonist with strong Phase 3 RCT evidence for IBS-C and CIC.

Dosing studied: 72 mcg/day (CIC adult, pediatric FC ages 2 and older) | 145 mcg/day (CIC adult; pediatric IBS-C ages 7 and older, Nov 2025 approval) | 290 mcg/day (IBS-C adult)
Read the evidence (key study, limitations)

~34% composite responder rate for IBS-C (290 mcg) vs. 14–21% placebo; NNT 5–8. Dual mechanism: luminal fluid secretion (CFTR activation) + visceral pain reduction (extracellular cGMP modulation of afferent nerves).

Key Study

Chey et al., Am J Gastroenterol 2012 (PMID 22986437): 26-week Phase 3 IBS-C RCT (n=800+); 33.7% responder rate vs. 13.9% placebo

Limitations

NNT 5–8 means ~65% of IBS-C patients are non-responders; diarrhea in 14–20% of patients requires dose reduction; no published head-to-head RCT vs. plecanatide; long-term data (>26 weeks) limited in adults

Community Experience
Strong
3.2/5
Based on n=500+ Reddit threads (r/ibs, r/Constipation)

Works rapidly for constipation relief but explosive diarrhea is the dominant complaint.

Community dosing: 72–145 mcg preferred by community for CIC due to diarrhea at 290 mcg; full 290 mcg used when abdominal pain is the primary complaint
Read the reports (what users report 4, common issues 5)

Dose paradox widely reported: lower doses (72–145 mcg) often tolerated better than 290 mcg with similar constipation benefit for a subset. Non-response in ~30–40% of real-world users.

What users report (4)
  • Rapid onset: bowel movement improvement within 24–48 hours
  • Abdominal pain and bloating reduction in IBS-C
  • Once-daily oral dosing, no injections required
  • Dose reduction to 72–145 mcg frequently achieves acceptable symptom control with less diarrhea
Common issues (5)
  • Explosive/urgent diarrhea: often described as unpredictable and disruptive (especially first 1–2 weeks at 290 mcg)
  • Strict 30-minute fasting window difficult to maintain consistently; missing it worsens diarrhea
  • High cash price (~$683/month) without insurance or manufacturer savings card
  • Non-response in a substantial minority (~30–40%) despite dose escalation
  • Symptoms return within ~1 week of stopping: perceived as dependency
Partially Aligned

Science and community agree on core efficacy for IBS-C/CIC and the diarrhea side effect profile. Key divergence: FDA approves 290 mcg as the IBS-C dose, but community frequently downdoses to 72–145 mcg due to intolerable diarrhea: a dose reduction strategy the FDA label also supports as a fallback. Community also reports the dose paradox (lower = better for some) which is mechanistically explained by near-maximal GC-C receptor occupancy at 72–145 mcg.

Linaclotide (Linzess) Dosage Guide

FDA LabelLinzess (linaclotide) FDA Prescribing Information (2025) (n=800+ (IBS-C phase 3 trials))Source (opens in a new tab)
LevelDoseFrequency
Beginner145 mcgDaily
Moderate145 mcgDaily
Aggressive290 mcgDaily
Note:

No vials, no syringes, no bacteriostatic water. Linaclotide is an oral capsule. Swallow it whole on an empty stomach, at least 30 minutes before eating. Set an alarm if that helps; the fasting window matters.

The 72 mcg dose covers CIC (adults) and pediatric functional constipation (ages 2 and older). The 145 mcg dose is for adult CIC and pediatric IBS-C (ages 7 and older). The 290 mcg dose targets adult IBS-C specifically.

If you can't swallow capsules, open them and sprinkle the beads onto room-temperature applesauce. Swallow immediately without chewing. They also work through NG or gastrostomy tubes mixed with water. Don't use hot food, don't chew the beads, don't store the mixture.

Store at room temperature (20 to 25 degrees C). No refrigeration needed.

One thing that catches people off guard: symptoms come back within about a week of stopping. This isn't dependency; it's just how local-acting drugs work. GC-C receptors don't desensitize, but they also don't stay activated once you stop providing the agonist.

Cycling

Linaclotide is intended for continuous daily use, not cycled. Clinical trials ran 12-26 weeks of uninterrupted dosing with sustained efficacy and no evidence of tachyphylaxis or tolerance. The FDA label does not specify a maximum treatment duration. Symptoms typically return within 1 week of discontinuation, as demonstrated in the 4-week randomized withdrawal phase of a Phase 3 IBS-C trial. Patients should continue taking linaclotide daily as long as the prescribing physician recommends.

Calculate your Linaclotide (Linzess) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Linaclotide (Linzess) Protocols by Goal

beginnerFDA LabelOngoing: symptoms return within ~1 week of discontinuation
Maintenance
Wk Ongoing (no maximum duration specified in FDA label)
72 mcg · Once daily · Oral capsule (swallowed whole)

Expected: Increased spontaneous bowel movement frequency; improved stool consistency; reduced bloating. Onset typically within 24–48 hours.

Monitor: Assess stool frequency and consistency at weeks 2 and 4. Check electrolytes if significant diarrhea occurs.

How to Use Linaclotide (Linzess)

  1. 1
    Step 1

    Take one capsule by mouth once daily, at least 30 minutes before the first meal of the day. The best timing is immediately after waking, before getting out of bed.

  2. 2
    Swallow the capsule whole with water

    Do not crush, break, or chew.

  3. 3
    Step 3

    If swallowing is difficult, open the capsule and sprinkle the beads onto a tablespoon of room-temperature applesauce. Swallow the mixture right away without chewing the beads. Do not store the mixture or mix with hot food.

  4. 4
    Step 4

    For tube-fed patients, the beads can be mixed with water and administered through a nasogastric or gastrostomy tube. Flush the tube with additional water afterward.

  5. 5
    Step 5

    No reconstitution, no refrigeration, no syringe calculations. This is an oral peptide. The capsule contains the full dose (72, 145, or 290 mcg depending on your prescription).

  6. 6
    Step 6

    Store capsules at controlled room temperature (20 to 25 degrees C). Excursions to 15 to 30 degrees C are acceptable. Do not freeze.

  7. 7
    Step 7

    If a capsule is accidentally opened and the beads look clumped or degraded, discard it and use a fresh capsule.

Alternative Routes

Capsule opened: beads on room-temperature applesauce

No dose adjustment: same bead content, identical bioactive dose

Swallow bead/applesauce mixture immediately without chewing beads. Do not mix with hot food or liquids. Do not store mixture after preparation. Bead matrix is protease-resistant and must not be crushed.

Nasogastric (NG) tube or gastrostomy tube

No dose adjustment

Mix capsule beads in water and administer via tube. Flush tube with additional water after administration. Used in hospitalized or tube-dependent patients.

Linaclotide (Linzess) Stacking Protocols

Works With

Avoid

Plecanatide (Trulance)

Same GC-C agonist mechanism: concurrent use produces additive GI fluid secretion with no additional efficacy benefit. Switching between them is clinically rational; concurrent use is not.

Do not combine
Lubiprostone (Amitiza)

Different secretagogue (ClC-2 chloride channel activator) but overlapping intestinal secretory effect. Concurrent use risks additive diarrhea and excessive fluid secretion.

Do not combine
Loperamide (Imodium)

Opioid receptor agonist that reduces GI motility and secretion: directly counteracts linaclotide's intended mechanism. Use negates the therapeutic purpose.

Do not combine

Estimated Cost

Brand Price
~$683/month retail (typical US cash price 2026, 290 mcg capsules, 30-count); WAC ~$567.97/month (Jan 2025). Manufacturer savings card (Ironwood/AbbVie Linzess Savings Program): $30/month for commercially insured patients, max $2,280/year savings.
Generic / Research
No generic available. Expected ~2029 (145/290 mcg strengths) or ~2031 (72 mcg); Mylan holds ANDA 209564 but is blocked by patent settlement. ~91% of insured prescriptions result in <$50/month copay.

Pricing updated 2026-04-09

Linaclotide (Linzess) Side Effects

The boxed warning comes first: linaclotide is contraindicated in children under 2 years of age. In neonatal mice, a single clinically relevant adult dose caused deaths from dehydration. Data on GC-C expression in children under 2 are too thin to rule that risk out. This is not a soft warning.

Diarrhea is the most common adverse effect, reported in 14 to 20% of patients across Phase 3 trials compared to 3 to 5% on placebo. It is dose-dependent, worst in the first 1 to 2 weeks (especially at 290 mcg), and typically improves as the GI tract adapts. The mechanism is straightforward: CFTR activation pulls fluid into the lumen, and the secretory effect doesn't always calibrate perfectly to each patient's GI capacity.

Community descriptions are blunter than the trial data suggests. The word "explosive" comes up frequently in r/ibs threads, along with reports of unpredictable urgency that disrupts daily routines. The practical workaround most users converge on is taking the dose immediately upon waking, before getting out of bed, so the urgency window happens during the morning routine.

Severe diarrhea requiring hospitalization has been reported in postmarketing surveillance. These rare cases sometimes involved dizziness, syncope, hypotension, or electrolyte abnormalities (hypokalemia, hyponatremia). Anyone on concurrent diuretics or ACE inhibitors should be monitored more closely for electrolyte shifts if diarrhea becomes persistent.

Other reported effects in clinical trials include abdominal pain, flatulence, abdominal distension, and headache, all at low rates. Nausea is rare.

The dose paradox is worth understanding. At 72 to 145 mcg, GC-C receptor occupancy is already near-maximal in many people. Going higher to 290 mcg increases luminal fluid secretion without proportionally improving constipation relief. If 290 mcg produces intolerable diarrhea, the FDA label supports stepping down to 145 or 72 mcg. Community users discovered this pattern independently; it now appears in roughly a third of user reports.

A practical note on timing: taking linaclotide within 30 minutes of food or with a high-fat meal significantly increases diarrhea rates per the PK data. The 30-minute fasting window is not optional.

Pregnancy status is Category C. No embryofetal toxicity was seen in animal studies, but human data is insufficient. Linaclotide is not absorbed systemically, which offers some reassurance, but prescribers should weigh the benefit against the uncertainty. Breastfeeding data is similarly limited, though negligible systemic absorption suggests low risk of infant exposure.

When to stop: persistent intolerable diarrhea that doesn't resolve with dose reduction, no improvement in stool frequency after 12 weeks, or any sign of GI obstruction.

Common Issues & Solutions

Explosive diarrhea at 290 mcg: FDA-supported dose reduction to 145 mcg is first-line response: many community users achieve equivalent constipation benefit at lower doses due to near-maximal GC-C occupancy at 72–145 mcg.

Unpredictable urgency: shift dosing to immediately upon waking before getting out of bed: the bowel response window is more predictable and less disruptive when the drug is taken before rising.

No effect despite correct timing: confirm strict 30-minute pre-meal fasting window; ingesting within 30 minutes of eating paradoxically increases diarrhea risk AND reduces constipation efficacy simultaneously (documented in PK study).

Bloating without constipation improvement: visceral pain and bloating response lags stool frequency improvement by 1–2 weeks (extracellular cGMP modulation of afferent nerves requires sustained GC-C activation). Give at least 4 weeks before concluding non-response.

No response at 12 weeks: responder/non-responder separation is evident by weeks 2–4; if neither pain nor stool frequency has improved by week 12, the drug is unlikely to work. Switch to plecanatide (lower diarrhea rate) or lubiprostone (different mechanism).

Ask AI about this page

Ask AI for a second opinion on Linaclotide (Linzess) dosing and side effects

Contraindications

  • Children under 2 years of age: BOXED WARNING, risk of serious dehydration (a single clinically relevant adult dose caused dehydration deaths in neonatal mice)
  • Known or suspected mechanical gastrointestinal obstruction
  • Known hypersensitivity to linaclotide or any capsule excipients
  • Pregnancy: Category C; insufficient human data, embryofetal toxicity not observed in animal studies but use only if benefit outweighs risk
  • Breastfeeding: linaclotide and its metabolite are not absorbed systemically, but caution is advised due to limited data
  • IBS-C in children under 7 years: safety and effectiveness not established (IBS-C is labeled for ages 7 and older)

Drug Interactions

  • Proton pump inhibitors (omeprazole, lansoprazole): may alter capsule dissolution timing; clinical significance unclear but no dose adjustment required per FDA label
  • Other secretagogues (lubiprostone, plecanatide): avoid concurrent use due to additive diarrhea risk and overlapping mechanisms
  • Antidiarrheal agents (loperamide): may counteract linaclotide's therapeutic effect; concurrent use undermines treatment rationale
  • Diuretics and ACE inhibitors: monitor for electrolyte imbalances if linaclotide-induced diarrhea is significant, particularly hypokalemia and hyponatremia
  • Drugs with narrow therapeutic index requiring consistent GI absorption (warfarin, digoxin, levothyroxine): increased intestinal fluid could theoretically alter absorption kinetics; monitor levels
  • Same GC-C agonist mechanism: concurrent use produces additive GI fluid secretion with no additional efficacy benefit. Switching between them is clinically rational; concurrent use is not.
  • Opioid receptor agonist that reduces GI motility and secretion: directly counteracts linaclotide's intended mechanism. Use negates the therapeutic purpose.

Product Quality

Recommended Monitoring

TestWhenTarget
Symptom diary / IBS-SSS (Irritable Bowel Syndrome Severity Scoring System)Baseline, weeks 2, 4, and 12IBS-SSS reduction >50 points = clinically meaningful response; FDA composite endpoint = ≥30% abdominal pain reduction + ≥1 additional CSBM/week for ≥6/12 treatment weeks
Basic metabolic panel (electrolytes: Na+, K+)If significant or persistent diarrhea occurs (>3 loose stools/day for >3 consecutive days)K+ 3.5–5.0 mEq/L; Na+ 135–145 mEq/L
Hydration assessmentFirst 2 weeks of initiation; any time diarrhea is significantNot listed
Symptom diary / IBS-SSS (Irritable Bowel Syndrome Severity Scoring System)

Quantifies IBS-C symptom severity (abdominal pain intensity/frequency, bloating, bowel satisfaction, stool consistency) to assess response and confirm responder status by week 12.

Basic metabolic panel (electrolytes: Na+, K+)

Diarrhea-induced hypokalemia and hyponatremia reported in rare postmarketing cases. Risk higher with concurrent diuretic use, renal impairment, or in elderly/pediatric patients.

Hydration assessment

Dehydration is the primary serious safety concern, especially in children (contraindicated <2 years) and elderly or renally impaired patients. Severe diarrhea cases have required hospitalization in postmarketing surveillance.

Linaclotide (Linzess) Before and After

Days 1-3

Begin once-daily dosing on an empty stomach 30 minutes before breakfast. Increased bowel movements may occur within 24 hours. Some patients experience loose stools or diarrhea in the first few days as the gut adjusts to increased fluid secretion. This typically self-resolves.

Week 1

Improvement in stool frequency and consistency is often measurable within the first week. Complete spontaneous bowel movements (CSBMs) increase. Abdominal bloating may begin to reduce. If diarrhea is persistent or severe, dose reduction (290 mcg to 145 mcg, or 145 mcg to 72 mcg) is appropriate.

Weeks 2-4

Sustained improvement in bowel habits. Abdominal pain reduction becomes more apparent as extracellular cGMP accumulates and modulates visceral afferent nerve signaling. In Phase 3 IBS-C trials, significant separation from placebo in pain scores was evident by week 2-3.

Weeks 4-12

Full therapeutic benefit established. In clinical trials, approximately 34% of IBS-C patients met the FDA composite responder endpoint (improvement in both pain and stool frequency) over 12 weeks. Benefits are sustained with continued daily dosing. No tolerance or dose escalation needed.

Month 3+

Long-term maintenance phase. A 26-week Phase 3 trial confirmed sustained efficacy without diminishing returns. Discontinuation leads to symptom recurrence within approximately 1 week, confirming the need for ongoing therapy. Annual reassessment with prescribing physician is recommended.

What to Expect

Days 1 to 3: GC-C receptor activation starts within hours of the first capsule. Most Phase 3 patients saw bowel movement improvement within 24 hours. Community reports confirm a strong first-day effect for many users, with urgency kicking in 1 to 3 hours after dosing. Others notice nothing for 2 to 3 days. Diarrhea, cramping, and flatulence tend to peak in this window, particularly at 290 mcg.

Week 1: Stool frequency picks up measurably. Complete spontaneous bowel movements (CSBMs) increase; stool consistency improves on the Bristol Stool Scale. Bloating may start easing. Diarrhea stabilizes for some users but remains problematic for others at the higher dose. Dose reduction requests are common at this point.

Weeks 2 to 4: Pain reduction becomes more noticeable. Phase 3 IBS-C trials showed significant separation from placebo in visceral pain scores by weeks 2 to 3. The extracellular cGMP pathway modulating afferent nerve signaling needs sustained activation to build up. Community users describe feeling "back to normal" during this stretch; a subset finds 145 mcg works as well as 290 mcg with fewer side effects.

Weeks 4 to 12: The responder/non-responder split becomes clear. Around 34% hit the FDA composite endpoint for IBS-C (pain reduction plus stool frequency gain). Benefits hold steady without dose escalation or tolerance. Non-responders typically recognize their status by weeks 4 to 8 and look for alternatives like plecanatide or lubiprostone.

Month 3 and beyond: Long-term maintenance. The 26-week Phase 3 trial confirmed sustained efficacy without diminishing returns. No tachyphylaxis or GC-C desensitization documented. Symptoms return within about a week of stopping (confirmed in the 4-week randomized withdrawal phase). Ongoing issues for long-term users are mainly cost (for uninsured patients) and occasional loose stools.

Detailed Timeline: Science vs Community

Days 1–3
Science

GC-C receptor activation occurs within hours of first dose. Luminal fluid secretion begins immediately, increasing transit speed. Bowel movement improvement observed within 24 hours in most Phase 3 patients.

Community

Strong first-day effect common: many describe urgency within 1–3 hours. Others notice nothing for 2–3 days. Diarrhea is typically worst in this window, especially at 290 mcg.

Week 1
Science

Significant increase in complete spontaneous bowel movements (CSBMs) vs. placebo measurable by week 1 in Phase 3 data. Bristol Stool Scale type improves (softer, better-formed stools).

Community

Most users notice clear improvement in bowel frequency. Bloating may begin to reduce. Diarrhea stabilizing for some; still problematic for others at 290 mcg. Many seek dose reduction at this point.

Weeks 2–4
Science

Significant separation from placebo in visceral pain scores by weeks 2–3 in Phase 3 IBS-C trials. Extracellular cGMP modulation of submucosal afferent nerve endings requires sustained receptor activation to accumulate.

Community

Pain and bloating relief becomes more apparent. Many users describe feeling "back to normal." Diarrhea stabilizes. Subset of users find 145 mcg achieves equivalent results to 290 mcg with fewer side effects.

Weeks 4–12
Science

~34% composite responder rate (IBS-C, 290 mcg); ~21–25% above placebo for CIC (145 mcg). Benefits sustained without dose escalation or attenuation across 12-week trial period.

Community

Clear responder/non-responder split. Non-responders typically recognize this by week 4–8 and seek alternatives. Responders report significant quality-of-life gains: less cramping, more predictable bowel habits.

Month 3+
Science

26-week Phase 3 trial confirmed sustained efficacy without attenuation. No tachyphylaxis, dose escalation, or GC-C desensitization documented. Symptoms return within ~1 week of stopping (confirmed in 4-week randomized withdrawal phase).

Community

Long-term users report stable, consistent benefit. Main ongoing issues are cost (for uninsured patients) and occasional loose stools. Annual prescriber reassessment recommended.

Pharmacokinetics

Half-Life
N/A
Bioavailability
Negligible (<0.1%): linaclotide acts entirely within the intestinal lumen and is not absorbed into the systemic circulation
Tmax
Not applicable: linaclotide is not systemically absorbed; peak luminal activity occurs in the small intestine shortly after oral ingestion
Data Confidence
high

Source: Systemic half-life is not measurable: linaclotide plasma concentrations are below the limit of quantification after therapeutic doses (72-290 mcg). The peptide and its active metabolite MM-419447 are degraded within ~1 hour in the intestinal lumen through disulfide bond reduction. The drug has no meaningful systemic PK (FDA label, Section 12.3)

Molecular Profile

Amino Acids
14
Structure
Cyclic
Sequence
CCEYCCNPACTGCY
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers

Who Should Consider Linaclotide (Linzess)

  • Adults with irritable bowel syndrome with constipation (IBS-C): FDA-approved at 290 mcg daily
  • Adults with chronic idiopathic constipation (CIC): FDA-approved at 72 mcg or 145 mcg daily
  • Pediatric patients aged 2 and older with functional constipation: FDA-approved at 72 mcg daily
  • Patients who have failed osmotic laxatives, fiber supplements, or other first-line constipation therapies
  • IBS-C patients with significant abdominal pain who need both motility and analgesic benefits

Related Peptides

What Changed for Linaclotide (Linzess)

  1. Dosing

    Corrected Oct 9, 2026: the linaclotide beginner tier is 145 mcg daily, the adult CIC dose; 72 mcg is a tolerability option, per the Linzess label.

    Before: Beginner 72 mcg daily After: Beginner 145 mcg daily; 72 mcg stays a label option for CIC by presentation or tolerability

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

  2. Safety

    Corrected Oct 7, 2026: the Linzess label contraindicates linaclotide under age 2, not under 6, and covers IBS-C from age 7, per the FDA label.

    Before: Children under 6 years of age: BOXED WARNING; not recommended for IBS-C in patients aged 6 to 17 years After: Children under 2 years of age: BOXED WARNING; IBS-C in children under 7: safety and effectiveness not established (labeled for ages 7 and older)

    What this does not mean: The label has said under 2 since August 2021. No new FDA safety action happened on this date; the page was out of date.

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

  3. Safety

    Corrected Oct 7, 2026: the boxed dehydration warning covers children under 2, not under 6, per the current Linzess label (SPL version 39).

    Before: The boxed warning comes first: linaclotide is contraindicated in children under 6 years of age. After: The boxed warning comes first: linaclotide is contraindicated in children under 2 years of age.

    Source: Linzess (linaclotide) prescribing information (openFDA label record, SPL version 39, effective May 21, 2026) (opens in a new tab) · Saved copy

Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations

References

  1. [1]Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety (Chey et al., Am J Gastroenterol 2012) (opens in a new tab)(n=800)PubMed (opens in a new tab)PubMed
  2. [2]FDA NDA 209564

Related Tools

Storage & Stability

Before Reconstitution
Store capsules at controlled room temperature (20-25°C), stable until expiration date on packaging
After Reconstitution
Not applicable: oral capsule formulation, no reconstitution needed
Temperature
20-25°C (68-77°F), excursions permitted to 15-30°C (59-86°F)

Frequently Asked Questions

The 30-minute fasting window isn't arbitrary. A PK study showed that taking linaclotide with a high-fat meal or within 30 minutes of eating significantly increased diarrhea rates and altered GI effects. The practical workaround most people use: take it immediately upon waking, before getting out of bed.

This comes up a lot in patient communities and it's a real phenomenon. At 72-145 mcg, GC-C receptor occupancy is already near-maximal in many people. Higher doses just increase luminal fluid secretion, which translates to diarrhea. Not better constipation relief. If 290 mcg gives you explosive diarrhea but insufficient pain relief, dose reduction to 145 or 72 mcg often achieves better overall symptom control.

Yes, the FDA label explicitly allows this. Sprinkle on room-temperature applesauce and swallow immediately without chewing. They can also go through an NG or gastrostomy tube mixed with water. Don't use hot food, don't chew the beads, and don't store the mixture after mixing.

For most people, it's worst in the first 1-2 weeks and modestly improves as the GI tract adapts. About 5-10% of patients have persistent diarrhea requiring dose reduction. If 290 mcg is intolerable, FDA-supported dose reduction to 145 or 72 mcg usually resolves it while keeping some therapeutic benefit.

Three months is a full therapeutic trial. Phase 3 data shows separation between responders and non-responders by weeks 2-4. If nothing has happened by 12 weeks, it's unlikely to start working. The responder rate is ~34% for IBS-C, meaning most patients either don't respond or respond only modestly. Time to try plecanatide or a different class.